T. Rowe Price Associates
VERA icon

T. Rowe Price Associates’s Vera Therapeutics VERA Stock Holding History

T. Rowe Price Associates’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172M Sell
4,012,936
-561,094
-12% -$20.9M 0.02% 546
2026
Q1 		$184M Sell
4,574,030
-887,946
-16% -$38.3M 0.02% 482
2025
Q4 		$277M Buy
5,461,976
+1,795,537
+49% +$63.8M 0.03% 367
2025
Q3 		$107M Sell
3,666,439
-813,278
-18% -$18.8M 0.01% 607
2025
Q2 		$106M Sell
4,479,717
-275,115
-6% -$6.19M 0.01% 559
2025
Q1 		$114M Buy
4,754,832
+377,783
+9% +$12.1M 0.01% 530
2024
Q4 		$185M Buy
4,377,049
+437,940
+11% +$19.4M 0.02% 448
2024
Q3 		$174M Buy
3,939,109
+318,974
+9% +$12.1M 0.02% 456
2024
Q2 		$131M Buy
3,620,135
+1,227,106
+51% +$48.7M 0.02% 487
2024
Q1 		$103M Buy
+2,393,029
New +$85.3M 0.01% 544

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's VERA Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Vera Therapeutics (VERA) stake by 12% in Q2 2026, selling an estimated $20.9M and leaving 4,012,936 shares worth $172M. The position accounts for 0.02% of the portfolio, ranked #546.

T. Rowe Price Associates first reported a position in VERA in Q1 2024 and has held it in 10 quarters since. The position peaked at $277M in Q4 2025. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • T. Rowe Price Associates held 4,012,936 shares of Vera Therapeutics worth $172M as of Q2 2026.
  • T. Rowe Price Associates sold 561,094 Vera Therapeutics shares in Q2 2026, an estimated $20.9M.
  • Vera Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #546 holding.
  • T. Rowe Price Associates first reported a position in Vera Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • T. Rowe Price Associates's Vera Therapeutics position peaked at $277M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.